




Journey Guidewire

COMPANY	Boston Scientific Corporation
PHONE	(888) 272-1001
WEB	www.bostonscientific.com/Journey
KEY FEATURES <ul style="list-style-type: none"> • 7.25-inch microcut nitinol sleeve promotes efficient energy transfer for turn-by-turn response and control • Kink-resistant nitinol core for excellent rail support and device delivery • Hybrid coating design promotes smooth tracking and enhanced tactile feedback. • Shapeable, radiopaque tip 	

Boston Scientific Corporation (Natick, MA) announced the launch of its Journey guidewire, an innovative 0.014-inch-diameter guidewire designed for use in challenging, small vessel peripheral angioplasty procedures. The Journey guidewire strengthens Boston Scientific's broad portfolio of devices designed to address physician needs in treating arteries below the knee.

It features a new microcut nitinol sleeve designed to provide efficient transmission of torque energy for more precise turn-by-turn response and control compared to conventional spring coil guidewires. The nitinol distal core and hybrid coating are designed to enhance wire durability, tactile response, and device delivery for improved overall performance.

"In my experience, the Journey guidewire provides exceptional torque and flexibility, particularly in difficult cases involving small vessels or tortuous anatomy," said Dr. James Benenati, Medical Director of the Cardiac and Vascular Institute in Miami and President of the Society of Interventional Radiology. "This highly durable guidewire offers outstanding precision and tracking to help access the toughest peripheral lesions."



IQCath Balloon Dilatation Catheter

COMPANY	Hotspur Technologies, Inc.
PHONE	(650) 969-3150
WEB	www.hotspur-inc.com
KEY FEATURES <ul style="list-style-type: none"> • 3-in-1 device: angioplasty, embolectomy coil, injection valve • Uses proprietary and innovative VisioValve technology • Robust balloon design • Delivered through a 6- or 7-F sheath 	

Hotspur Technologies, Inc. (Mountain View, CA) announced that the US FDA granted the company 510(k) clearance to market the IQCath balloon dilatation catheter for use in dialysis applications. The IQCath is a specialty 3-in-1 device that allows physicians to efficiently perform angioplasty, deliver physician-specified fluids, and perform thrombectomy without exchanging catheters or jeopardizing the guidewire position in synthetic arteriovenous fistulae, the company stated. Delivered through a 6- or 7-F sheath, the device uses proprietary and innovative VisioValve technology, located on the distal tip, injecting physician-specified fluids, including contrast and thrombolytics, without removing or moving the guidewire. IQCath's robust balloon design is nominal at 8 atm and has a rated burst pressure of 16 or 20 atmospheres. The three Hotspur products that have received FDA clearance are the IQCath balloon dilatation catheter, GPSCath balloon dilatation catheter, and Keeper embolectomy catheter. They are expected to be commercially available by the end of 2010 and can all be used for dialysis applications, while the GPSCath and Keeper catheters also have indications for PAD procedures.



The Talent Captivia System

COMPANY	Medtronic, Inc.
WEB	www.medtronic-endovascular.com
KEY FEATURES <ul style="list-style-type: none"> • Tip-capture mechanism • Hydrophilic coating • Lengths up to 200 mm • Three-step deployment process 	

Medtronic, Inc. (Minneapolis, MN) announced US Food and Drug Administration approval of the Talent thoracic stent graft with the Captivia delivery system for the endovascular repair of fusiform aneurysms and saccular aneurysms/penetrating ulcers of the descending thoracic aorta in appropriately selected patients. Talent Captivia features a tip capture mechanism for controlled deployment and precise placement of the implantable medical device.



In addition to tip capture, the Captivia delivery system features a hydrophilic coating to ease insertion into the femoral artery and navigation through the iliac arteries en route to the aorta. It is available in lengths up to 200 mm for fewer passes in difficult-to-navigate iliac arteries, the company stated. ■

Subscribe to *Endovascular Today's* eNews

Our biweekly electronic newsletter can be delivered directly to your email account, bringing you industry and clinical news updates between our print issues. Subscribing is easy and free. Simply email us at evtenews@bmctoday.com, type "Subscribe eNews" in the subject line, and include your name in the body of the email. You can unsubscribe at any time by clicking on the "unsubscribe" link in the eNewsletter.

We look forward to hearing from you!

